Crinetics Pharmaceuticals Inc [CRNX] stock prices are down -1.11% to $44.43 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CRNX shares have gain 6.60% over the last week, with a monthly amount glided 30.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $36. Previously, Stifel started tracking the stock with Buy rating on March 25, 2025, and set its price target to $60. On February 11, 2025, TD Cowen initiated with a Buy rating. Wolfe Research started tracking the stock assigning a Peer Perform rating. Jefferies upgraded its rating to a Buy but $55 remained the price target by the analyst firm on January 22, 2025. Citigroup started tracking with a Buy rating for this stock on March 06, 2024, and assigned it a price target of $68. In a note dated January 16, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $50 on this stock.
The stock price of Crinetics Pharmaceuticals Inc [CRNX] has been fluctuating between $24.10 and $62.53 over the past year. Currently, Wall Street analysts expect the stock to reach $85.75 within the next 12 months. Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] shares were valued at $44.43 at the most recent close of the market. An investor can expect a potential return of 93.0% based on the average CRNX price forecast.
Analyzing the CRNX fundamentals
Gross Profit Margin for this corporation currently stands at -0.11% with Operating Profit Margin at -303.92%, Pretax Profit Margin comes in at -265.69%, and Net Profit Margin reading is -265.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.32 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Crinetics Pharmaceuticals Inc [NASDAQ:CRNX]’s Current Ratio is 17.80. Further, the Quick Ratio stands at 17.80, while the Cash Ratio is 0.79. Considering the valuation of this stock, the price to sales ratio is 3010.25, the price to book ratio is 3.57.
Transactions by insiders
Recent insider trading involved Pizzuti Dana, Chief Med and Dev Officer, that happened on Oct 01 ’25 when 5000.0 shares were sold. Officer, DANA PIZZUTI completed a deal on Oct 01 ’25 to buy 5000.0 shares. Meanwhile, President & CEO Struthers Richard Scott sold 4000.0 shares on Sep 26 ’25.
